4597.T Solasia Pharma JPX JPY 29.00 after-hours 05 Feb 2026: earnings catalyst eyed

The most active after-hours name on JPX tonight is 4597.T stock, trading at JPY 29.00 on 05 Feb 2026 with volume at 36,460,000.00 shares. Activity follows a thin float and upcoming earnings on 13 Feb 2026. Traders are reacting to a negative EPS of -8.96 and a PE of -3.24, while healthcare peers trade at materially higher multiples. We use this after-hours move to outline near-term drivers and risks for Solasia Pharma K.K. (4597.T) on JPX using Meyka AI-powered market analysis tools

Price snapshot: 4597.T stock after-hours

Solasia Pharma K.K. (4597.T) is quoted at JPY 29.00 in after-hours trade on JPX. The intraday band ran JPY 28.00 to JPY 30.00 and year range sits between JPY 27.00 and JPY 48.00. Volume last trade was 36,460,000.00, slightly below the 30-day average of 40,630,391.00, giving a relative volume of 0.91.

Fundamentals and valuation: earnings and balance sheet

Solasia posts an EPS of -8.96 and a PE of -3.24, reflecting persistent losses. Market cap equals 7415296143.00 JPY. The company shows cash per share 7.05 and book value per share 6.92, with a current ratio of 4.57. Price-to-sales is 22.75, far above Healthcare sector average PE of 23.49 and PS norms. These metrics underline a research-heavy, low-revenue profile and valuation disconnect versus larger peers.

Technical and trading flow: indicators that matter

Momentum reads mixed: RSI is 45.38, MACD is -0.93 with a histogram of 0.11, and ADX at 26.39 signals a trending move. Bollinger middle band is 29.45 and ATR is 1.66, showing modest intraday volatility. On-balance volume is strongly negative, but high intraday turnover makes Solasia one of tonight’s most active JPX names. Technicals suggest short-term consolidation ahead of earnings.

Pipeline, catalysts and sector context

Solasia focuses on oncology products including SP-03, SP-01 and late-stage SP-02 and SP-05 programs. The company employs 23.00 staff and targets Asian markets. Upcoming catalysts include the earnings release on 13 Feb 2026 and any clinical updates on SP-05. The Healthcare sector in Japan has shown moderate gains YTD, but Solasia’s clinical risk and thin revenue stream make it an outlier in sector performance.

Meyka AI rates 4597.T with a score out of 100

Meyka AI rates 4597.T with a score out of 100: 63.59, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade balances cash reserves and pipeline value against weak earnings and high price-to-sales. These grades are informational only and are not investment advice.

Forecasts, targets and risk-adjusted view

Meyka AI’s forecast model projects a yearly price of JPY 26.70, implying -7.91% from the current JPY 29.00. A conservative price target is JPY 24.00 (downside -17.24%), a base case is JPY 29.00 (flat), and an optimistic target is JPY 40.00 (upside 37.93%). Forecasts are model-based projections and not guarantees. Key risks include continued net losses, trial setbacks, and thin liquidity.

Final Thoughts

4597.T stock traded actively after hours at JPY 29.00 on 05 Feb 2026, driven by thin float, high turnover and the upcoming earnings release on 13 Feb 2026. Fundamentals show a loss-making drug developer with EPS -8.96, PE -3.24, robust cash per share 7.05, and a high price-to-sales ratio 22.75 versus Healthcare peers. Technical signals point to short-term consolidation while fundamental catalysts remain binary. Meyka AI’s forecast model projects JPY 26.70 for the year, an implied downside of -7.91% versus today’s price. Traders seeking exposure should weigh clinical and earnings risk against the potential upside from successful trial news. For quick reference and follow-up, see the company site and our coverage pages, including the Meyka stock page for 4597.T for real-time updates

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.